• Dennis Limmer
• 27 Jul, 2024

The European Medicines Agency (EMA) has denied approval for lecanemab, a drug being currently developed to help against Alzheimer’s. It has been reported that the drug has been showing the ability to start slowing cognitive decline. However, the EMA also concluded that there are indeed some risks and also possible severe side effects such as brain bleeding and swelling.
Read more...